C
Chen Wang
Researcher at Mayo Clinic
Publications - 198
Citations - 15466
Chen Wang is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Medicine & Serous fluid. The author has an hindex of 33, co-authored 159 publications receiving 11490 citations. Previous affiliations of Chen Wang include Shanghai Jiao Tong University & University of Science and Technology of China.
Papers
More filters
Journal ArticleDOI
Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma
Emilien Loeuillard,Jingchun Yang,Eee L.N. Buckarma,Juan Wang,Yuanhang Liu,Caitlin B. Conboy,Kevin D. Pavelko,Ying Li,Daniel R. O'Brien,Chen Wang,Rondell P. Graham,Rory L. Smoot,Haidong Dong,Sumera Ilyas +13 more
TL;DR: It is identified that tumor-associated macrophages (TAMs) are the primary source of PD-L1 in human and murine CCA and the therapeutic potential of coupling ICB with immunotherapies targeting immunosuppressive myeloid cells in CCA is highlighted.
Journal ArticleDOI
Association of Serum Retinol-Binding Protein 4 and Visceral Adiposity in Chinese Subjects with and without Type 2 Diabetes
TL;DR: Serum RBP4 level is positively associated with visceral adiposity in both men and women and may contribute to the development of insulin resistance along with other adipokines.
Journal ArticleDOI
Clinical Characteristics of Ovarian Cancer Classified by BRCA1, BRCA2, and RAD51C Status
Julie M. Cunningham,Mine S. Cicek,Nicholas B. Larson,Jaime I. Davila,Chen Wang,Melissa C. Larson,Honglin Song,Ed Dicks,Patricia Harrington,Myra J. Wick,Boris Winterhoff,Habib Hamidi,Gottfried E. Konecny,Jeremy Chien,Marina Bibikova,Jian-Bing Fan,Kimberly R. Kalli,Noralane M. Lindor,Brooke L. Fridley,P Pharoah,Ellen L. Goode +20 more
TL;DR: HRD patients with germline or somatic alterations in any gene were more likely to be high grade serous, have an earlier diagnosis age and have ovarian and/or breast cancer family history, and Identification of EOC patients with an HRD phenotype may help tailor specific therapies.
Journal ArticleDOI
Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes
Stefan Kommoss,Boris Winterhoff,Boris Winterhoff,Ann L. Oberg,Gottfried E. Konecny,Chen Wang,Shaun M. Riska,Jian-Bing Fan,Matthew J. Maurer,Craig April,Viji Shridhar,Friedrich Kommoss,Andreas du Bois,Felix Hilpert,Sven Mahner,Klaus Baumann,W. Schroeder,Alexander Burges,Ulrich Canzler,Jeremy Chien,Andrew C. Embleton,Mahesh K. B. Parmar,Richard Kaplan,Timothy J. Perren,Lynn C. Hartmann,Ellen L. Goode,Sean C. Dowdy,Jacobus Pfisterer +27 more
TL;DR: Validation of the findings in an independent cohort could enable the use of bevacizumab for those patients most likely to benefit, thereby reducing side effects and healthcare cost.
Journal ArticleDOI
MACE: model based analysis of ChIP-exo
Liguo Wang,Liguo Wang,Junsheng Chen,Chen Wang,Liis Uusküla-Reimand,Kaifu Chen,Alejandra Medina-Rivera,Edwin J. Young,Michael T. Zimmermann,Huihuang Yan,Zhifu Sun,Yuji Zhang,Stephen Wu,Haojie Huang,Michael D. Wilson,Jean Pierre A. Kocher,Wei Li +16 more
TL;DR: MACE is able to define transcription factor binding site (TFBS) boundaries with high sensitivity, specificity and spatial resolution, as evidenced by multiple criteria including motif enrichment, sequence conservation, direct sequence pileup, nucleosome positioning and open chromatin states.